共 23 条
[1]
Arnold D(2017)Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab Ann Oncol 28 2932-2942
[2]
Fuchs CS(2010)Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 780-787
[3]
Tabernero J(2017)Review article: the diagnostic approach and current management of chylous ascites Aliment Pharmacol Ther 46 816-824
[4]
Spratlin J(2013)Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature PLoS One 8 e74686-108
[5]
Cohen R(2007)Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas BMC Cancer 7 105-undefined
[6]
Eadens M(2015)Simultaneous chylothorax and chylous ascites in a patient with castration-resistant prostate cancer after docetaxel chemotherapy: an unusual manifestation Int J Urol 22 614-undefined
[7]
Lizaola B(2018)Surgical treatment following chemo-targeted therapy with bevacizumab for lung metastasis from colorectal carcinoma: analysis of safety and histological therapeutic effects in patients treated at a single institution Case Rep Oncol 11 98-undefined
[8]
Bonder A(undefined)undefined undefined undefined undefined-undefined
[9]
Trivedi HD(undefined)undefined undefined undefined undefined-undefined
[10]
Dellinger MT(undefined)undefined undefined undefined undefined-undefined